12:39 PM EST - Revive Therapeutics Ltd : Announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with rheumatic diseases. The article described that antibody levels were significantly lower in the groups treated with TNF inhibitor with methotrexate, abatacept, mycophenolate mofetil, MMF or mizoribine combined with calcineurin inhibitor, and rituximab or cyclophosphamide compared with those treated with sulfasalazine and/or Bucillamine or CNI. The newly published study further validates the potential of Bucillamine in the treatment course for COVID-19. Revive Therapeutics Ltd
shares C.RVV are trading up one cent at $0.32.
